$Coles Group Ltd (COL.AU)$: Barrenjoey has an overweight rating and A$22.00 target price on the stock.
Coles' cost blowout on its new automated distribution systems takes the gloss off the supermarket chain's FY 2022 performance, according to Barrenjoey analysts. They tell clients in a note that an early read of the Australian firm's result suggests that it is in line with market expectations, but they point out that total opera...

Hey moo-ers,
Get ready for another launch of a new version of our moomoo Umbrella this week on 8 July (Friday) at 10:00！Rain or shine, our chic moomoo Umbrella’s got you covered!
Fastest fingers first! Redeem the moomoo umbrella for just 15,000 points.
*Available in two colors - orange and black.
View what’s available on Rewards Club now
$Futu Holdings Ltd (FUTU.US)$

$AMC Entertainment (AMC.US)$  Had to buy more AMC at these discounts this morning😊🤙
💎🙌🦍=🔥🚀🦍🌙

Looking to travel this year? Then we've got just the perfect item you need! Our exclusive 5-pc travel organiser (15,000 points) will help make packing and unpacking a breeze!
Mark your calendars! Our travel organiser will be launched on Rewards Club this Friday, 13 May at 10:00am SGT.
Limited pieces available so grab yours before it gets fully redeemed!
$Futu Holdings Ltd (FUTU.US)$

Fixed-interest reits
$W.P. Carey Inc (WPC.US)$  $Simon Property (SPG.US)$  $NNN REIT (NNN.US)$An excellent choice for investment portfolios

$Seagate Technology (STX.US)$ up

$Johnson & Johnson (JNJ.US)$ $SINOPHARM (01099.HK)$ COVID-19 vaccines from U.S. drugmaker Johnson & Johnson and China's Sinopharm as well as Russia's Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.
The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.
Vaccines from $Moderna (MRNA.US)$ , $ASTRAZENECA PLC (AZNCF.US)$ and $Pfizer (PFE.US)$ and partner $BioNTech (BNTX.US)$ retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.
The study also found that while the effectiveness of $GlaxoSmithKline (GSK.US)$ and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.
The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.

$Takung Art (TKAT.US)$ I'm so disappointed